MultiPlan (NYSE:MPLN - Free Report) had its price target lifted by Citigroup from $10.00 to $12.50 in a research report sent to investors on Friday,Benzinga reports. They currently have a neutral rating on the stock.
MultiPlan Stock Up 3.2 %
NYSE:MPLN traded up $0.40 during trading hours on Friday, hitting $12.77. 115,535 shares of the company traded hands, compared to its average volume of 173,639. The company has a debt-to-equity ratio of 21.73, a quick ratio of 1.05 and a current ratio of 1.05. The firm has a market cap of $206.50 million, a P/E ratio of -0.13 and a beta of 0.10. The business's 50-day simple moving average is $9.00. MultiPlan has a one year low of $4.80 and a one year high of $53.60.
Hedge Funds Weigh In On MultiPlan
Several institutional investors have recently modified their holdings of MPLN. Hsbc Holdings PLC raised its position in MultiPlan by 68.7% in the second quarter. Hsbc Holdings PLC now owns 218,459 shares of the company's stock worth $87,000 after acquiring an additional 88,944 shares during the period. Point72 DIFC Ltd bought a new position in MultiPlan during the second quarter valued at $43,000. Cubist Systematic Strategies LLC purchased a new stake in MultiPlan in the second quarter worth $72,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of MultiPlan in the second quarter valued at $245,000. Finally, AQR Capital Management LLC lifted its position in shares of MultiPlan by 386.2% during the 2nd quarter. AQR Capital Management LLC now owns 2,742,735 shares of the company's stock valued at $1,065,000 after buying an additional 2,178,590 shares during the last quarter. 87.15% of the stock is owned by institutional investors.
MultiPlan Company Profile
(
Get Free Report)
MultiPlan Corporation, together with its subsidiaries, provides data analytics and technology-enabled cost management, payment, and revenue integrity solutions to the healthcare industry in the United States. The company offers analytics-based services that reduce medical costs, through data-driven algorithms and insights that detect claims over-charges and negotiate or recommend reimbursement; and network-based services that provide contracted discounts with healthcare providers, as well as outsourced network development and management services.
Featured Stories
Before you consider MultiPlan, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MultiPlan wasn't on the list.
While MultiPlan currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
